NIKKEI 225
26,362.43 -442.17 (-1.65%) HANG SENG
21,982.64 -14.25 (-0.06%) CRUDE OIL
109.94 +0.16 (+0.15%) GOLD FUTURES
1,817.10 -0.40 (-0.02%) DOW
31,029.31 +82.32 (+0.27%) BTC-GBP
16,473.96 -255.48 (-1.53%)
DBV Technologies S.A. (DBVT)
- Globe Newswire
DBV Technologies to Participate in Upcoming EAACI 2022 Congress
Montrouge, France, June 28, 2022 DBV Technologies to Participate in Upcoming EAACI 2022 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming participation at the hybrid in-person and virtual European Academy of Allergy and Clinical Immunology (EAACI) Annual Scientific meeting, July 1 – 3, 2022, in Prague, Czech Republic. Two scientific presentations have been accepted, including one non-cl
- Globe Newswire
DBV Technologies to Present at the JMP Securities Life Sciences Conference in New York
Montrouge, France, June 16, 2022 DBV Technologies to Present at the JMP Securities Life Sciences Conference in New York DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, and Dr. Pharis Mohideen, Chief Medical Officer, will participate in a fireside chat on Thursday, June 16, 2022, at 12:00 p.m. ET at the JMP Securities Life Sciences Conference in New York. A we
- Globe Newswire
DBV Technologies Announces Private Placement Financing of $194 Million
Montrouge, France, June 9, 2022 DBV Technologies Announces Private Placement Financing of $194 Million DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Global Select Market: DBVT), a clinical-stage biopharmaceutical company, today announced an aggregate $194 million private investment in public equity (PIPE) financing (corresponding to €181 million on the basis of an exchange rate of $1.0739 = €1.00 published by the European Central Bank on June 8, 2022) from the sale of 32,855,669
